ss than 10% of the dose of CORVERT is excreted unchanged in the urine; and (3) drug distribution appears to be one of the primary mechanisms responsible for termination of the pharmacologic effect. Nonetheless, patients with abnormal liver function should be monitored by telemetry for more than the 4-hour period generally recommended.
In 285 patients with atrial fibrillation or atrial flutter who were treated with CORVERT, the clearance of ibutilide was independent of renal function, as assessed by creatinine clearance (range 21 to 140 mL/min).
ADVERSE REACTIONS
CORVERT Injection was generally well tolerated in clinical trials. Of the 586 patients with atrial fibrillation or atrial flutter who received CORVERT in phase II/III studies, 149 (25%) reported medical events related to the cardiovascular system, including sustained polymorphic ventricular tachycardia (1.7%) and nonsustained polymorphic ventricular tachycardia (2.7%).
Other clinically important adverse events with an uncertain relationship to CORVERT include the following (0.2% represents one patient): sustained monomorphic ventricular tachycardia (0.2%), nonsustained monomorphic ventricular tachycardia (4.9%), AV block (1.5%), bundle branch block (1.9%), ventricular extrasystoles (5.1%), supraventricular extrasystoles (0.9%), hypotension/postural hypotension (2.0%), bradycardia/sinus bradycardia (1.2%), nodal arrhythmia (0.7%), congestive heart failure (0.5%), tachycardia/sinus tachycardia/supraventricular tachycardia (2.7%), idioventricular rhythm (0.2%), syncope (0.3%), and renal failure (0.3%). The incidence of these events, except for syncope, was greater in the group treated with CORVERT than in the placebo group.
Another adverse reaction that may be associated with the administration of CORVERT was nausea, which occurred with a frequency greater than 1% more in ibutilide-treated patients than those treated with placebo.
The medical events reported for more than 1% of the placebo- and ibutilide-treated patients are shown in the following Table.
Treatment-Emergent Medical Events With Frequency of More Than 1% and Higher Than That of Placebo
Event Placebo
N=127 All Ibutilide
N=586
Patients Patients
n % n %
CARDIOVASCULAR
Ventricular extrasystoles 1 0.8 30 5.1
Nonsustained monomorphic VT 1 0.8 29 4.9
Nonsustained polymorphic VT — — 16 2.7
Hypotension 2 1.6 12 2.0
Bundle branch block — — 11 1.9
Sustained polymorphic VT — — 10 1.7
AV block 1 0.8 9 1.5
Hypertension — — 7 1.2
QT segment prolonged — — 7 1.2
Bradycardia 1 0.8 7 1.2
Palpitation 1 0.8 6 1.0
Tachycardia 1 0.8 16 2.7
GASTROINTESTINAL
Nausea 1 0.8 11 1.9
CENTRAL NERVOUS SYSTEM
Headache 4 3.1 21 3.6
In the post-cardiac surgery study (see CLINICAL STUDI |
